George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
…except of course, for the incessant noise of tummies rumbling. :)
You are right though. I worked in the import business for over 20 years, specialising in food stuffs and spices. Ramadan didn’t stop a single Muslim making a hard earned buck.
Why would I include “… but to what effect... great positive upward SP news or equally for the negative."? My post was about you making a statement of fact, when it most certainly isn’t fact. The other bit which you think I edited, is you speculating which I have no problem with.
“I would rather buy in low (as I have done) and sit on them for a while…”
I did that three years ago…it didn’t work! :0D)
“Clearly he has been told not to comment on social media for breaching PLC guidelines,…”
Or,…. things are going a bit tits-up and he’s strategically and hastily retreated back into his box.
Not saying that’s true, just that assumption is a sport for fools.
Cost to benefit would’ve done that in mate. You’ve got Pfizer, Oxford AZ, Moderna et al who were all placed at the right time with modifications to already existing SARS vaccines. Logistically and financially, developing CBR for Covid is a waste. That’s why I think the focus will now be on ‘niche’ viruses that aren’t satisfied by existing therapies. I think there’ll still be half an eye on Covid as that little blighter may yet evolve into something a lot more sinister in the future. If that happens, we’ll all be multi-millionaires but we’d also be dead.
Nope!
Lol…and for the cherry on top, you’re also a condescending pr…k
Aseptic techniques are a cornerstone of medical and scientific delivery. If anyone past their first year at university doesn’t know the importance of aseptic techniques or how to use and maintain a sterile environment, then they have business being anywhere near scientific research.
There’s countless CAR-T projects going on at the moment around the world and many at more advanced stages. Apart from a few deals in 2017/18, I see zero evidence of appetite for acquisitions by large pharmaceutical companies. I guess this may be the year for the Bio sector to go all M&A crazy but that’s all it is, a guess…but I don’t think so.
Hemo will need to sink or swim on its own. Hence the recent raise, Vlad can’t afford to be over-confident.
One thing to consider, the financial sector, after doing their own due diligence, aren’t going to commit themselves to a project that could be scuppered by an over eager local politician. I get that they wont put their hand in their pocket until the ESIA is awarded, but neither do they want to appear foolish by backing a white elephant.
Nearly down to my buy in price of 2020…! :0(
Sorry for being a pedant but it’s ‘moot’…moot point. This ranks nearly as high in the ‘grinds my gears’ stakes as ‘damp squid’…arrrggghhhh!
Steady Ed’, we’ll be accused of being a herd soon.
TP asks some very pertinent questions. I’m aware some think he’s annoying but that shouldn’t distract from the legitimacy of his questions.
It’s not as if Nanoco didn’t spell it out as plainly as they possibly could…”a settlement that we feel is fair”. For a company with less than a three million a year turnover, the settlement was hardly going to be in the multiple hundreds of millions.